J&J Medical Connect
DARZALEX FASPRO®

(daratumumab and hyaluronidase-fihj)

This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

Patient Medical Information

What is the Recommended Dosing for DARZALEX FASPRO in Combination With Bortezomib, Melphalan, and Prednisone to Treat Multiple Myeloma?

Last Updated: 04/22/2024

summary

The following information from the DARZALEX FASPRO PRESCRIBING INFORMATION and MEDICATION GUIDE may be helpful in addressing your question1:

  • The recommended dose of DARZALEX FASPRO is 1800 mg/30,000 units (1800 mg daratumumab and 30,000 units hyaluronidase).
  • DARZALEX FASPRO will be given to you by your healthcare provider as an injection under the skin, in the stomach area (abdomen).
  • DARZALEX FASPRO is injected over 3 to 5 minutes.
  • The dosing schedule of DARZALEX FASPRO when administered in combination with bortezomib, melphalan, and prednisone (VMP) is summarized in the Figure: Dosing Schedule for DARZALEX FASPRO in Combination With VMP.

Abbreviations: VMP, bortezomib + melphalan + dexamethasone; Wk, week.
aDARZALEX FASPRO (Prescribing Information)1

  • Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
  • Your healthcare provider will give you medicines before each dose of DARZALEX FASPRO and after each dose of DARZALEX FASPRO to help reduce the risk of serious allergic reactions and other reactions due to release of certain substances by your body (systemic).
  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

additional information

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT MEDICATION GUIDE for DARZALEX FASPRO.1

 

References

1 DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf.